Tarsus Pharmaceuticals: Q2 2026 Rebound In Sales Possible, Catalysts Approaching (TARS)

Tarsus Pharmaceuticals reported a dip in Xdemvy net product sales in Q1 2026, the first quarterly decline since the drug launched. The drop followed a strong Q4 2025 and raised questions about whether the Demodex blepharitis treatment had hit a plateau.

The company has not yet released Q2 results. A return to sequential growth would signal that the Q1 stumble was a temporary pause, not the start of a slowdown. Tarsus is expected to report second-quarter earnings in the coming months.

Several potential catalysts are on the calendar, including label expansion efforts and pipeline updates. The stock will likely trade on whether Xdemvy can regain its growth trajectory.